Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Alta Bates Summit Medical Center, The Research and Education Development Institute
mi
from 43215
Berkeley, CA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Alta Bates Summit Medical Center, The Research and Education Development Institute
mi
from 43215
Berkeley, CA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Neurology Associates, PA
788
mi
from 43215
Maitland, FL
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Neurology Associates, PA
788
mi
from 43215
Maitland, FL
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
University of Miami
992
mi
from 43215
Miami, FL
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
University of Miami
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Collier Neurologic Specialists
957
mi
from 43215
Naples, FL
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Collier Neurologic Specialists
957
mi
from 43215
Naples, FL
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Neurological Services Orlando
796
mi
from 43215
Orlando, FL
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Neurological Services Orlando
796
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Meridien Research
830
mi
from 43215
Tampa, FL
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Meridien Research
830
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Vero Beach Neurology
864
mi
from 43215
Vero Beach, FL
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Vero Beach Neurology
864
mi
from 43215
Vero Beach, FL
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Shepherd Center
432
mi
from 43215
Atlanta, GA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Shepherd Center
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Consultants in Neurology, Ltd.
292
mi
from 43215
Northbrook, IL
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Consultants in Neurology, Ltd.
292
mi
from 43215
Northbrook, IL
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Fort Wayne Neurological Center
133
mi
from 43215
Fort Wayne, IN
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Fort Wayne Neurological Center
133
mi
from 43215
Fort Wayne, IN
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Josephson Wallack Munshower Neurology P.C
158
mi
from 43215
Indianapolis, IN
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Josephson Wallack Munshower Neurology P.C
158
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Associates in Neurology
154
mi
from 43215
Lexington, KY
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Associates in Neurology
154
mi
from 43215
Lexington, KY
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Saint Elizabeth's Medical Center
643
mi
from 43215
Boston, MA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Saint Elizabeth's Medical Center
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Island Neurological Assoicates, PC
505
mi
from 43215
Plainview, NY
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Island Neurological Assoicates, PC
505
mi
from 43215
Plainview, NY
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
University Hospital and Medical Center Stony Brook New York
524
mi
from 43215
Stony Brook, NY
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
University Hospital and Medical Center Stony Brook New York
524
mi
from 43215
Stony Brook, NY
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Carolinas Medical Center - Neurology
350
mi
from 43215
Charlotte, NC
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Carolinas Medical Center - Neurology
350
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
The Neurological Institute
348
mi
from 43215
Charlotte, NC
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
The Neurological Institute
348
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Pmg Research Of Charlotte
351
mi
from 43215
Charlotte, NC
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Pmg Research Of Charlotte
351
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Neurology Specialists
63
mi
from 43215
Dayton, OH
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Neurology Specialists
63
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Providence Medical Group - Medford
2060
mi
from 43215
Medford, OR
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Providence Medical Group - Medford
2060
mi
from 43215
Medford, OR
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Providence St. Vincent Medical Center - Northwest MS Center
2026
mi
from 43215
Portland, OR
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Providence St. Vincent Medical Center - Northwest MS Center
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
The Maxine Mesinger MS Clinic/Baylor College of Medicine
991
mi
from 43215
Houston, TX
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
The Maxine Mesinger MS Clinic/Baylor College of Medicine
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Central Texas Neurology
1051
mi
from 43215
Round Rock, TX
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Central Texas Neurology
1051
mi
from 43215
Round Rock, TX
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Integra Clinical Research
1132
mi
from 43215
San Antonio, TX
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Integra Clinical Research
1132
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Fletcher Allen Health Care - Neurology Service
590
mi
from 43215
Burlington, VT
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Fletcher Allen Health Care - Neurology Service
590
mi
from 43215
Burlington, VT
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Hampton Roads Neurology
407
mi
from 43215
Newport News, VA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Hampton Roads Neurology
407
mi
from 43215
Newport News, VA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Neurological Associates, Inc.
339
mi
from 43215
Richmond, VA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Neurological Associates, Inc.
339
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Swedish Neuroscience Institute
1991
mi
from 43215
Issaquah, WA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Swedish Neuroscience Institute
1991
mi
from 43215
Issaquah, WA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Swedish Neuroscience Institute
2005
mi
from 43215
Seattle, WA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Swedish Neuroscience Institute
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
University of Ottawa
529
mi
from 43215
Ottawa,
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
University of Ottawa
529
mi
from 43215
Ottawa,
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
494
mi
from 43215
Homewood, AL
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
494
mi
from 43215
Homewood, AL
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
1648
mi
from 43215
Gilbert, AZ
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
1648
mi
from 43215
Gilbert, AZ
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
1991
mi
from 43215
Hanford, CA
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
1991
mi
from 43215
Hanford, CA
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
2035
mi
from 43215
Modesto, CA
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
2035
mi
from 43215
Modesto, CA
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
1960
mi
from 43215
Santa Ana, CA
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
1960
mi
from 43215
Santa Ana, CA
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
510
mi
from 43215
Danbury, CT
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
510
mi
from 43215
Danbury, CT
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
668
mi
from 43215
Jacksonville, FL
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
668
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
561
mi
from 43215
Savannah, GA
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
561
mi
from 43215
Savannah, GA
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
179
mi
from 43215
Avon, IN
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
179
mi
from 43215
Avon, IN
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
164
mi
from 43215
Franklin, IN
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
164
mi
from 43215
Franklin, IN
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
125
mi
from 43215
Muncie, IN
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
125
mi
from 43215
Muncie, IN
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
624
mi
from 43215
Overland Park, KA
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
624
mi
from 43215
Overland Park, KA
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
643
mi
from 43215
Boston, MA
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
630
mi
from 43215
Golden Valley, MN
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
630
mi
from 43215
Golden Valley, MN
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
301
mi
from 43215
Amherst, NY
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
301
mi
from 43215
Amherst, NY
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
494
mi
from 43215
New Hyde Park, NY
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
494
mi
from 43215
New Hyde Park, NY
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
481
mi
from 43215
New York, NY
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials